title: Stage IB endometrial cancer. Does lymphadenectomy replace adjuvant radiotherapy?
abstract: BACKGROUND
  The role of surgical lymph node dissection and adjuvant radiation therapy (RT) in early stage endometrial cancer is no longer clearly defined. The increased appreciation of lymphadenectomy and the absence of survival advantage from adjuvant RT rise controversies how patients should adequately be treated in stage IB endometrial cancer. The aim of this review is to rule out the validity of either treatment option and determine which preference provides the best therapeutic benefit.
  
  
  METHODS
  Reports of relevant studies obtained from a search of PubMed and studies referenced in those reports were reviewed.
  
  
  RESULTS
  Based on the available data in the literature, for stage IB grade 1 or 2, the risk of pelvic relapse is considered too low to justify pelvic RT. However, intravaginal RT (IVRT) should be recommended for those >or= 60 years old or with lymphovascular invasion (LVI). For patients with stage IB grade 3 (and IC all grades), the treatment recommendation is mainly based on whether surgical lymph node staging was performed. These patients have--without surgical lymph node staging--a high risk of pelvic recurrence and should therefore primarily undergo relaparotomy for lymphadenectomy or pelvic RT as second choice. If these patients had a surgical lymph node staging, then IVRT alone is a reasonable alternative to pelvic RT.
  
  
  CONCLUSIONS
  Overall survival may not be the only ideal endpoint for stage IB endometrial cancer since causes of death are mostly other than endometrial cancer. Conventional pelvic RT may be overtreatment in some patients, in particular in those patients with a large number of negative lymph nodes after lymphadenectomy. However, negative surgical staging should not be understood as adjuvant RT can be omitted in all patients.
authors.affiliation: Department of Radiotherapy and Radiation Oncology, University Hospital, Ulm, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Bottke
authors.forename: Thomas
authors.initials: T
authors.lastname: Wiegel
authors.forename: Rolf
authors.initials: R
authors.lastname: Kreienberg
authors.forename: Christian
authors.initials: C
authors.lastname: Kurzeder
authors.forename: Georg
authors.initials: G
authors.lastname: Sauer
mesh_terms: D000206:Actuarial Analysis; D000367:Age Factors; D001918:Brachytherapy; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D004717:Endometrium / Q000473:pathology; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D050397:Radiotherapy, Intensity-Modulated; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors